The Absence of Corticosteroids in ARDS Guidelines

The speakers discuss the absence of corticosteroids in the 2023 ESICM guidelines for ARDS and question why they are not addressed. They explore the most appropriate corticosteroid agent, dose, and duration for ARDS, highlighting the studies on methylprednisolone and dexamethasone. They discuss the benefits of dexamethasone over methylprednisolone.